» Articles » PMID: 31906729

Therapeutic Targets for Liver Regeneration After Acute Severe Injury: a Preclinical Overview

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2020 Jan 8
PMID 31906729
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

: Liver transplantation is the only viable treatment with a proven survival benefit for acute liver failure (ALF). Donor organ shortage is, however, a major hurdle; hence, alternative approaches that enable liver regeneration and target acute severe hepatocellular damage are necessary.: This article sheds light on therapeutic targets for liver regeneration and considers their therapeutic potential. ALF following extensive hepatocyte damage and small-for-size syndrome (SFSS) are illuminated for the reader while the molecular mechanisms of liver regeneration are assessed in accordance with relevant therapeutic strategies. Furthermore, liver background parameters and predictive biomarkers that might associate with liver regeneration are reviewed.: There are established and novel experimental strategies for liver regeneration to prevent ALF resulting from SFSS. Granulocyte-colony stimulating factor (G-CSF) is a promising agent targeting liver regeneration after acute severe injury. Autophagy and hepatocyte senescence represent attractive new targets for liver regeneration in acute severe hepatic injury. Liver support strategies, including tissue engineering, constitute novel regenerative means; the success of this is dependent on stem cell research advances. However, there is no firm clinical evidence that these supportive strategies may alleviate hepatocellular damage until liver transplantation becomes available or successful self-liver regeneration occurs.

Citing Articles

Grand Challenges in Organ Transplantation.

Kupiec-Weglinski J Front Transplant. 2024; 1:897679.

PMID: 38994397 PMC: 11235338. DOI: 10.3389/frtra.2022.897679.


G-CSF promotes the viability and angiogenesis of injured liver via direct effects on the liver cells.

Liu Z, Zhang G, Tong J, Wang H, Chen J, Yang D Mol Biol Rep. 2022; 49(9):8715-8725.

PMID: 35781603 PMC: 9463201. DOI: 10.1007/s11033-022-07715-4.


Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity.

Hirao H, Nakamura K, Kupiec-Weglinski J Nat Rev Gastroenterol Hepatol. 2021; 19(4):239-256.

PMID: 34837066 DOI: 10.1038/s41575-021-00549-8.


A comprehensive investigation on liver regeneration: a meta-analysis and systems biology approach.

Asnaashari S, Amjad E, Sokouti B Clin Exp Hepatol. 2021; 7(2):183-190.

PMID: 34295986 PMC: 8284170. DOI: 10.5114/ceh.2021.107564.


Extracts Accelerate Liver Regeneration a Complex Network of Pathways.

Zou Y, Zhang M, Zeng D, Ruan Y, Shen L, Mu Z Front Pharmacol. 2020; 11:1174.

PMID: 32848780 PMC: 7413023. DOI: 10.3389/fphar.2020.01174.

References
1.
Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W . RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med. 2005; 201(3):473-84. PMC: 2213026. DOI: 10.1084/jem.20040934. View

2.
Sellaro T, Ranade A, Faulk D, McCabe G, Dorko K, Badylak S . Maintenance of human hepatocyte function in vitro by liver-derived extracellular matrix gels. Tissue Eng Part A. 2009; 16(3):1075-82. PMC: 2863084. DOI: 10.1089/ten.TEA.2008.0587. View

3.
Ikegami T, Nishizaki T, Yanaga K, Shimada M, Kishikawa K, Nomoto K . The impact of donor age on living donor liver transplantation. Transplantation. 2001; 70(12):1703-7. DOI: 10.1097/00007890-200012270-00007. View

4.
Nickkholgh A, Maluf D . Emerging graft protective strategies in clinical liver transplantation. Expert Rev Gastroenterol Hepatol. 2017; 11(7):623-631. DOI: 10.1080/17474124.2017.1322901. View

5.
Fausto N . Liver regeneration: from laboratory to clinic. Liver Transpl. 2001; 7(10):835-44. DOI: 10.1053/jlts.2001.27865. View